SNSW(SH:688117) Xin Lang Cai Jing·2025-12-30 10:59Core Viewpoint - The company announced that its wholly-owned subsidiary, Shengnuo Pharmaceutical, has signed a framework contract to supply GLP-1 peptide raw materials, with a total contract value not exceeding RMB 350 million, effective until December 31, 2025 [1] Group 1 - The contract was signed with a customer for the supply of GLP-1 peptide raw materials [1] - The total contract amount is capped at RMB 350 million, including tax [1] - The performance period of the contract extends from the signing date until December 31, 2025 [1] Group 2 - The company is actively promoting the cooperation process following the contract signing [1] - The progress of the contract's execution has been delayed due to the slow commercialization of the end customer's products [1] - The company believes there is a risk that the framework contract may not be fully executed [1]